CLAIMS DATA ANALYSIS OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) IN GERMANY

被引：0
|
作者：
Bartsch, R. [1 ]
Zimmermann, L. [2 ]
Reis, L. [1 ]
Hecker, D. [3 ]
Lebioda, A. [3 ]
机构：
[1] Amgen GmbH, Munich, Germany
[2] Gesundheitsforen Leipzig GmbH, Leipzig, Germany
[3] Amgen GmbH, Munich, Germany
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN177
引用
收藏
页码：S453 / S453
页数：1
相关论文
共 50 条
  • [41] How to Identify the Right Patients for the Right Treatment in Metastatic Colorectal Cancer (mCRC)
    Saridaki, Zenia
    Asimakopoulou, Natalia
    Boukovinas, Ioannis
    Souglakos, John
    CURRENT COLORECTAL CANCER REPORTS, 2015, 11 (04) : 151 - 159
  • [42] Single institution experience in treatment of elderly patients with metastatic colorectal cancer (MCRC)
    Zivi, A.
    Di Seri, M.
    Rossi, L.
    Graziano, V
    Tomao, S.
    Proietti, E.
    Cerbone, L.
    Russillo, M.
    Sacco, P. C.
    Longo, F.
    ANNALS OF ONCOLOGY, 2006, 17 : XI46 - XI46
  • [43] Phase II study of capecitabine and gemcitabine in patients with metastatic colorectal cancer (mCRC)
    Iqbal, S.
    Yang, D.
    Cole, S.
    El-Khoueiry, A. B.
    Boswell, W.
    Agafitei, R.
    Lujan, R.
    Lenz, H. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis.
    Hech, JR
    Patnaik, A
    Malik, I
    Venook, A
    Berlin, J
    Croghan, G
    Wiens, BL
    Visonneau, S
    Jerian, S
    Meropol, NJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 247S - 247S
  • [45] Preliminary data on weekly irinotecan (CPT) with continuous capecitabine (X) in metastatic colorectal cancer (MCRC) patients (pts).
    Anderson, N
    Lokich, J
    Kalman, L
    Bertoli, L
    Foulke, R
    Ratner, L
    Weitberg, A
    Burris, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 307S - 307S
  • [46] Treatment patterns and outcomes in metastatic colorectal cancer (mCRC).
    Cartwright, Thomas H.
    Wen, Lonnie Kent
    Harrell, Robyn K.
    Fox, Patricia S.
    Espirito, Janet L.
    Wang, Ed
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [47] Predictors of attrition in the treatment of metastatic colorectal cancer (MCRC).
    Bahrabadi, Arvin
    Ruan, Jenny
    Gresham, Gillian
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Treatment of metastatic colorectal cancer (mCRC) according to age
    Ortega, Laura
    Torres Perez-Solero, Gabriela
    Arregui Valles, Marta
    Alva Bianchi, Manuel
    Aparicio Salcedo, Inmaculada
    Garcia Gonzalez, Gonzalo
    Gallego Gallego, Iria
    Munoz Martin, Andres J.
    Calvo Ferrandiz, Aitana
    Blanco-Codesido, Montserrat
    Martin, Miguel
    Garcia-Alfonso, Pilar
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [49] Panitumumab (pmab) in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC): Final analysis from a community-based, observational study (VECTOR) in Germany
    Lerchenmuller, Christian A.
    Groschek, Matthias
    Kroening, Hendrik
    Scheuer, Burkhard
    Stauch, Martina
    Kuhn, Anja
    Hellebrand, Eva
    Vehling-Kaiser, Ursula
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [50] Characterization of best responder patients to oxaliplatin rechallenge in patients with refractory metastatic colorectal cancer (mCRC)
    Salva, F.
    Garcia, A.
    Saoudi, N.
    Baraibar, I.
    Ros, J.
    Comas, R.
    Ruiz, F.
    Rezqallah, A.
    Cuadra, J.
    Dientsmann, R.
    Tabernero, J.
    Elez, E.
    ANNALS OF ONCOLOGY, 2022, 33 : S243 - S244
12345